Jean Jacques Bienaime Biomarin Pharmaceutical Inc (BMRN) insider trading activity

Jean Jacques Bienaime is Director of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 473,792 shares of BMRN, which is worth approximately $30.1 Million. The most recent transaction as insider was on May 20, 2024, when has been sold 1,202 shares (Common Stock) at a price of $77.05 per share, resulting in proceeds of $92,614. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 474K

0% 3M change

12.08% 12M change

Total Value Held $30.1 Million

JEAN JACQUES BIENAIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 20 2024	SELL Payment of exercise price or tax liability	$92,614 $77.05 p/Share	1,202 Reduced 0.25%	473,792 Common Stock
May 10 2024	SELL Open market or private sale	$1,622,800 $81.14 p/Share	20,000 Reduced 4.04%	474,994 Common Stock
May 10 2024	BUY Exercise of conversion of derivative security	$1,262,000 $63.1 p/Share	20,000 Added 3.88%	494,994 Common Stock
May 09 2024	SELL Open market or private sale	$1,632,400 $81.62 p/Share	20,000 Reduced 4.04%	474,994 Common Stock
May 09 2024	BUY Exercise of conversion of derivative security	$1,262,000 $63.1 p/Share	20,000 Added 3.88%	494,994 Common Stock
Apr 12 2024	SELL Open market or private sale	$1,825,200 $91.26 p/Share	20,000 Reduced 4.04%	474,994 Common Stock
Apr 12 2024	BUY Exercise of conversion of derivative security	$1,262,000 $63.1 p/Share	20,000 Added 3.88%	494,994 Common Stock
Apr 11 2024	SELL Open market or private sale	$1,819,800 $90.99 p/Share	20,000 Reduced 4.04%	474,994 Common Stock
Apr 11 2024	BUY Exercise of conversion of derivative security	$1,262,000 $63.1 p/Share	20,000 Added 3.88%	494,994 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$7,146,478 $83.87 p/Share	85,209 Reduced 15.21%	474,994 Common Stock
Mar 06 2024	SELL Open market or private sale	$86,710 $86.71 p/Share	1,000 Reduced 0.18%	560,203 Common Stock
Mar 05 2024	SELL Open market or private sale	$85,510 $85.51 p/Share	1,000 Reduced 0.18%	561,203 Common Stock
Feb 27 2024	SELL Open market or private sale	$90,350 $90.35 p/Share	1,000 Reduced 0.18%	562,203 Common Stock
Feb 27 2024	BUY Grant, award, or other acquisition	-	143,601 Added 20.32%	563,203 Common Stock
Feb 09 2024	SELL Open market or private sale	$1,324,200 $88.28 p/Share	15,000 Reduced 3.45%	419,602 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	$946,500 $63.1 p/Share	15,000 Added 3.34%	434,602 Common Stock
Feb 08 2024	SELL Open market or private sale	$1,346,550 $89.77 p/Share	15,000 Reduced 3.45%	419,602 Common Stock
Feb 08 2024	BUY Exercise of conversion of derivative security	$946,500 $63.1 p/Share	15,000 Added 3.34%	434,602 Common Stock
Jan 18 2024	BUY Small Acquisition	$3,704 $92.6 p/Share	40 Added 0.01%	419,602 Common Stock
Jan 10 2024	SELL Open market or private sale	$963,800 $96.38 p/Share	10,000 Reduced 2.3%	425,162 Common Stock
Jan 10 2024	BUY Exercise of conversion of derivative security	$631,000 $63.1 p/Share	10,000 Added 2.25%	435,162 Common Stock
Jan 09 2024	SELL Open market or private sale	$981,900 $98.19 p/Share	10,000 Reduced 2.3%	425,162 Common Stock
Jan 09 2024	BUY Exercise of conversion of derivative security	$631,000 $63.1 p/Share	10,000 Added 2.25%	435,162 Common Stock
Jan 08 2024	BUY Small Acquisition	$4,952 $99.05 p/Share	50 Added 0.01%	425,162 Common Stock
Dec 21 2023	SELL Open market or private sale	$939,900 $93.99 p/Share	10,000 Reduced 2.3%	425,112 Common Stock

Also insider at

INCY

INCYTE CORP Healthcare

Director

KROS

Keros Therapeutics, Inc. Healthcare

IMNM

Immunome Inc. Healthcare

JJB